search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
News


Cancer care improving, but gaps remain in emotional support


The latest National Cancer Patient Experience Survey has found sustained improvements in how well services involve patients’ families and carers, with small gains in communication and information. The survey, commissioned by NHS England and conducted by Picker, received more than 64,000 responses from people who had recently received cancer treatment. As well as showing positive experiences in many


areas, it highlights opportunities to strengthen support beyond treatment, particularly access to emotional support in the community. Last year’s survey showed improvements in how well NHS hospitals involve patients’ families and carers. These improvements have been sustained, with further gains in some areas: l 83% said they were told they could have a family member, carer or friend with them when they were told their diagnosis, unchanged from 2024 and up from 70% during the COVID pandemic in 2021.


l 85% said their family or carers were “definitely”


involved in decisions about treatment options as much as they wanted, unchanged from 2024 and up from 75% in 2021.


l Measures relating to support for families and carers continued to improve, with 72% saying those close to them could “definitely” talk to the care team at hospital when needed (71% in 2024; 61% in 2021), and 64% saying family members, or someone close, received the information needed to support care for the patient at home (63% in 2024; 55% in 2021).


l68% said that their referral for diagnosis was explained in a way they could “completely” understand, up from 67% in 2024 and 64% in 2021.


l 84% said healthcare staff appeared to have all the information they needed about them at the time of diagnostic tests, up from 83% in 2024 (unchanged from 2021).


l 88% received easy to understand information about what they should or should not do after leaving hospital, up from 87% in 2024, though still below the 89% reported in 2021.


l The proportion offered information about how to get financial help or benefits fell slightly to 71% (72% in 2024), although this remains above the 2021 figure of 70%.


While most patients reported positive experiences of hospital care, only 33% said they could “definitely” access enough emotional support at home from community or voluntary services after treatment, a slight decrease from 34% in 2024 and unchanged from 2021.


Thousands eligible for new chronic heart failure treatment


Final draft guidance from NICE now


recommends finerenone for adults with chronic heart failure with preserved or mildly reduced ejection fraction. Heart failure with preserved or mildly


reduced ejection fraction happens when the left side of the heart doesn’t fill properly with blood during the diastolic (filling) phase. This means the heart is unable to pump enough blood to meet the body’s needs. Heart failure with preserved or mildly reduced ejection fraction means the reduction in blood pumped is smaller than for heart failure with reduced ejection fraction. Finerenone is a type of treatment called a mineralocorticoid receptor antagonist (MRA). Unlike other MRAs, finerenone is nonsteroidal and so may be used by more people. “Not only does finerenone have the potential


to help them live well for longer, but it could also save the NHS money and free up space by reducing their risk of having to go to hospital for unplanned emergency treatment,” commented Helen Knight, director of medicines evaluation at NICE.


Of the estimated 635,000 people in England


who have heart failure, half have preserved or mildly reduced ejection fraction. There were around 100,000 hospitalisations in England for heart failure in 2023 to 2024, making it one of the leading causes of avoidable hospital admissions.


Draeger signs strategic partnership with Guy’s and St Thomas’ Toni Schrofner, Dräger Board Member and Chief


Draeger Medical UK and Guy’s and St Thomas’ NHS Foundation Trust have signed a pioneering three-year strategic partnership that will see the organisations work together to develop and explore next-generation medical technologies designed to improve patient care and clinical outcomes. The agreement, the first of its kind between


Dräger and an NHS organisation, establishes a long-term strategic partnership focused on collaboration, innovation and the future of healthcare delivery, intending to support key NHS priorities, including accelerating digital adoption, delivering more care closer to home, and shifting the focus of healthcare from treatment to prevention. Bringing together frontline clinicians, technical specialists and Dräger’s world-leading healthcare technology research and development


12 www.clinicalservicesjournal.com I September 2026


engineers, the partnership will create opportunities to explore new solutions and technologies across critical areas of healthcare, including anaesthesia and perioperative care. As part of the collaboration, clinicians from Guy’s


and St Thomas’ will work directly with Dräger’s research and development teams at the company’s global headquarters in Lübeck, Germany, helping to ensure future technologies are shaped by real- world clinical expertise and the evolving needs of patients and healthcare professionals. Designed to support the NHS’s long-term ambitions for healthcare transformation, the strategic partnership creates a flexible model for innovation that can evolve alongside the needs of the Trust, allowing both organisations to respond to emerging challenges and opportunities in patient care.


Officer of Dräger’s Medical Division, commented: “For more than 135 years, innovation has been at the heart of Dräger. This partnership represents exactly the kind of collaboration needed to address the increasingly complex challenges facing healthcare systems around the world. By working closely with one of the United Kingdom’s largest and leading NHS trusts, we have a unique opportunity to combine clinical expertise with our leading research and development capabilities to create technologies that improve patient outcomes and support healthcare professionals in delivering the highest standards of care. We see this as a partnership built not only for today’s challenges, but for the needs of future generations, reflecting our values as a fifth-generation family-owned business with a history of healthcare innovation.”


Africa Studio - stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85